Supplementary Tables

Table S1. HLA matching status between CB-MNCs donors, A673 cells and B-ALL PDX cells

Tumor sample	CB-MNCs donors 1	2	3
A673 cells	HLA class I: HLA-B HLA class II: HLA-DRB1, DQB1	HLA class I: HLA-A No match HLA class II	HLA class I: HLA-A HLA class II: HLA-DRB1
B-ALL PDX cells	HLA class I: HLA-A,-B HLA class II: HLA-DRB1, DQB1, DQA1, DPB1, DPA1	No match HLA class I HLA class II: DPB1, DPA1	No match HLA class I HLA class II: DRB1, DQB1, DQA1, DPB1, DPA1

Supplementary Figures



Supplementary Figure 1. **Expanded human immune cell populations delay B-ALL engraftment in NSGS mice humanized with CB-MNCs. (A)** Schematic representation of the experimental design used to assess *in vivo* the tumor immunity in a B-ALL context. **(B,C)** Total HLA-ABC+hCD45+ engraftment (**B**) and proportion of immune populations within the HLA+hCD45+ human graft (**C**) in PB and BM from NSGS mice transplanted with CB-MNCs before B-ALL-PDX inoculation (week 7). **(D)** Weekly monitoring of B-ALL graft (HLA-ABC+hCD45+CD19+) in PB from humanized and non-humanized NSGS mice. **(E)** Correlation at endpoint (two weeks after B-ALL infusion) between B-ALL engraftment levels and human NK and T cell levels in PB, BM, liver and spleen. Each dot represents an independent mouse. *p<0.05, Pearson correlation test.